-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The drug will be used in clinical trials for idynic pulmonary fibrosis.
FTP-198 is a class 1 innovative chemical developed by our company for the treatment of idiotic pulmonary fibrosis (IPF).
IPF is a chronic, aggressive fibrosis lung disease with unknown epathy, which can cause peripheral pulmonary fibrosis remodeling, leading to respiratory failure, the incidence of which increases with age, and is common in people aged 60 to 70 years, and is the most common idynogenic interstitity pneumonia.
IPF diagnosis after the median survival of 2 to 5 years, high mortality rate, is the respiratory system of the incurable diseases of the Company and all members of the Board of Directors to ensure that the information disclosure content is true, accurate, complete, no false records, misleading statements or major omissions.
of 2 diseases.
, IPF has not been a significantly effective treatment, so there is an urgent need for a new treatment that is effective and more to-bearable.
The target mechanism of this product is clear, there is the potential for expandable adaptive disorders, in addition to fibrosis and tumors, but also includes angiogenesic, autoimmune diseases, inflammation, NASH, neurodegenerative lesions and other adaptive disorders, the company will be based on the situation of the species or will carry out the above-mentioned expansion of adaptive disease research and development.
FTP-198 passed the Australian Ethics Review in January 2020 and conducted a single/multiple dose, randomized, double-blind, placebo-controlled, dose incremental study of healthy people in the first quarter of 2020.
based on current results, it is expected to be a potential best-in-class treatment for idiotreatable pulmonary fibrosis (IPF).
。